All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2448 / 5) by Felicia Gomez, from Washington University, St. Louis, MO, et al. titled “Deep exome sequencing reveals recurrent somatic mutations in Hodgkin's Lymphoma” was presented.
The group hypothesized that recurrent somatic mutations can be recognized in Hodgkin Reed-Sternberg (HRS) cells, taken from biopsies of bulk Hodgkin Lymphoma (HL), using ultra-deep exome sequencing.
The poster concluded by stating that recurrent mutations in cHL can be identified using ultra-deep sequencing of bulk tumor tissue. The group identified previously unreported mutations which require validation, as well as known mutations. This data improves our understanding of the pathogenesis of cHL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox